Results 91 to 100 of about 160,832 (337)

CypA Mediates Non‐Small Cell Lung Cancer Chemoresistance by Attenuating Ferroptosis via Stabilizing SLC7A11

Advanced Science, EarlyView.
Summary diagram for the role of CypA in chemoresistance in non‐small cell lung cancer (NSCLC). CypA is overexpressed in chemoresistance NSCLC and drives therapeutic evasion by competitively binding to the K37 site of SLC7A11, thereby blocking TRIM3 mediated K11‐linked ubiquitination and proteasomal degradation, ultimately inhibiting lipid peroxidation ...
Zhongcheng Wang, An Li, Ziwei Song, Xiangming Liu, Yong Ge, Zhiqiao Chen, Yuhui Liu, Boyu Zhang, Hao Zhang, Ting Lan   +9 more
wiley   +1 more source

RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine

International Journal of Nanomedicine, 2019
Wenchao Liu1,2, Yujia Mao1,2, Xiaoyi Zhang1,2, Yaonan Wang1,2, Jianhui Wu1,2, Shurui Zhao1,2, Shiqi Peng1,2, Ming Zhao1–3 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of ...
Liu W, Mao Y, Zhang X, Wang Y, Wu J, Zhao S, Peng S, Zhao M   +7 more
doaj  

cNEK6 induces gemcitabine resistance by promoting glycolysis in pancreatic ductal adenocarcinoma via the SNRPA/PPA2c/mTORC1 axis

Cell Death and Disease
Resistance to gemcitabine in pancreatic ductal adenocarcinoma (PDAC) leads to ineffective chemotherapy and, consequently, delayed treatment, thereby contributing to poor prognosis. Glycolysis is an important intrinsic reason for gemcitabine resistance as
Ge Li, Fei-Fei She, Cheng-Yu Liao, Zu-Wei Wang, Yi-Ting Wang, Yong-Din Wu, Xiao-Xiao Huang, Cheng-Ke Xie, Hong-Yi Lin, Shun-Cang Zhu, Yin-Hao Chen, Zhen-heng Wu, Jiang-Zhi Chen, Shi Chen, Yan-Ling Chen   +14 more
doaj   +1 more source

Leveraging 3D Molecular Spatial Visual Information and Multi‐Perspective Representations for Drug Discovery

Advanced Science, EarlyView.
A deep learning framework called MolVisGNN is proposed to fuse 3D molecular visual information of drugs with multi‐source features, which proves the importance of 3D molecular visual information of drugs and the advancedness of this model in the field of drug discovery, and provides a reference for how to more comprehensively express small molecule ...
Zimai Zhang, Xi Zhou, Yujie Qi, Xiaobo Zhu, Xun Deng, Feng Tan, Yuan Huang, Lun Hu, Zhuhong You, Pengwei Hu   +9 more
wiley   +1 more source

Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells. [PDF]

, 2017
Precision cancer medicine seeks to target the underlying genetic alterations of cancer; however, it has been challenging to use genetic profiles of individual patients in identifying the most appropriate anti-cancer drugs. This spurred the development of
Dall'Era, Marc A, de Vere White, Ralph W, Gheibi, Pantea, Ma, Ai-Hong, Pan, Chong-Xian, Revzin, Alexander, Son, Kyung Jin, Vu, Tam, Yap, Stanley Alexander, Zeng, Shuxiong   +9 more
core   +2 more sources

NIR‐Activatable Domino Cascade Catalysis Nanozyme Reactor for Multi‐Mechanism Synergistic Immunotherapy in Bladder Cancer

Advanced Science, EarlyView.
This study presents an intravesical delivery strategy of ferroptosis‐ and immunity‐inducing nanozyme‐loaded thermoresponsive hydrogels (FMCC@PNH) for enhanced bladder cancer therapy. Abstract Current intravesical therapies for bladder cancer after resection are limited by poor tissue penetration, off‐target effects, and insufficient efficacy.
Yongnan Jiang, Qingling Zhang, Yuhan Zhang, Xinlu Yu, Bo Jia, Yulong Dong, Yalong Wu, Kelong Fan, Xinquan Gu, Lei Ji, Wei Jiang, Bin Liu   +11 more
wiley   +1 more source

Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity [PDF]

, 2016
BACKGROUND: Lung cancer is the leading cause of cancer related deaths and Malignant Pleural Effusion (MPE) is a frequent complication. Current therapies suffer from lack of efficacy in a great percentage of cases, especially when cancer is diagnosed at ...
CHERUBINI, EMANUELA, DE VITIS, CLAUDIA, Fabiana Fosca Ferrara, Francesca Bergantino, Francesca Fenizia, Gennaro Ciliberto, GIARNIERI, Enrico, GIOVAGNOLI, Maria Rosaria, Luigi Aurisicchio, MANCINI, RITA, MARIOTTA, Salvatore, Matilde Lambiase, Nicola Normanno, NOTO, ALESSIA, RICCI, Alberto, ROSCILLI, GIUSEPPE, Susan Costantini, TORRISI, Maria Rosaria   +17 more
core   +3 more sources

Early Detection of Chemotherapy‐Induced Glucose Metabolic Alterations in Bladder Carcinoma Using Deuterium (2H) Metabolic Imaging: in Vitro and in Vivo Assessments

Advanced Science, EarlyView.
This study presents the first application of deuterium metabolic imaging (DMI) for assessing therapeutic response in bladder cancer. Employing [2,3,4,6,6′‐2H5]‐D‐glucose, DMI successfully identified chemotherapy‐induced suppression of glycolysis both in vitro and in vivo.
Lingmin Kong, Ganghan Yang, Bei Weng, Zhihua Wen, Joshua D. Kaggie, Qian Cai, Qian Wan, Cuien Zheng, Feng Du, Ye Li, Xin Liu, Ferdia A. Gallagher, Yan Guo, Shi‐Ting Feng, Chao Zou, Huanjun Wang   +15 more
wiley   +1 more source

Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine

Molecules, 2017
One of the main obstacles for cancer therapies is to deliver medicines effectively to target sites. Since stroma cells are developed around tumors, chemotherapeutic agents have to go through stroma cells in order to reach tumors.
Yasuhiro Tsume, Adam J. Drelich, David E. Smith, Gordon L. Amidon   +3 more
doaj   +1 more source

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. [PDF]

, 2016
BackgroundHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies.
Cortes, Javier, Hurvitz, Sara A, Krop, Ian E, Miller, Kathy, Molnar, Istvan, Reynolds, Joseph G, Riahi, Kaveh, Tripathy, Debu, Verma, Sunil, Wickham, Thomas J, Yardley, Denise A   +10 more
core   +2 more sources